-+ 0.00%
-+ 0.00%
-+ 0.00%

Genmab says Phase 1/2 RAINFOL-01 Rina-S plus bevacizumab shows tolerable safety profile

PUBT·04/13/2026 13:35:24
Listen to the news
Genmab says Phase 1/2 RAINFOL-01 Rina-S plus bevacizumab shows tolerable safety profile
  • Genmab reported Phase 1/2 RAINFOL-01 data already presented at 2026 SGO showing rinatabart sesutecan (Rina-S) combined with bevacizumab was tolerable in advanced ovarian cancer.
  • Safety profile was consistent with known effects of both drugs, with no new safety signals reported.
  • Genmab highlighted absence of specific high-concern toxicities seen with some oncology agents, supporting feasibility of combination use.
  • Ongoing Phase 3 RAINFOL-04 will further evaluate Rina-S with bevacizumab in recurrent platinum-sensitive ovarian cancer, positioning regimen for potential late-stage development readouts.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via Business Wire (Ref. ID: 202604130935BIZWIRE_USPR_____20260410_BW050131) on April 13, 2026, and is solely responsible for the information contained therein.